2024
GP100 expression is variable in intensity in melanoma
Mann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorFemaleGp100 Melanoma AntigenHumansImmunohistochemistryMaleMelanomaMiddle AgedSkin NeoplasmsConceptsGp100 expressionCutaneous melanomaTreatment of cutaneous melanomaAdvanced cutaneous melanomaT-cell engagersImprove patient selectionMetastatic melanomaUveal melanomaMetastatic samplesPatient selectionClinical trialsMelanomaQuantitative immunofluorescence methodGp100Improve outcomesImmunofluorescence methodTherapeutic intentDrugCellular productsExpressionTebentafuspImmunohistochemistry
2008
Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions
Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Modern Pathology 2008, 21: 1121-1129. PMID: 18552823, PMCID: PMC2570478, DOI: 10.1038/modpathol.2008.100.Peer-Reviewed Original ResearchAntigens, NeoplasmBiomarkers, TumorCell NucleusDiagnosis, DifferentialFluorescent Antibody Technique, IndirectGp100 Melanoma AntigenHumansImage Processing, Computer-AssistedImmunoenzyme TechniquesMelanomaMelanoma-Specific AntigensMembrane GlycoproteinsNeoplasm ProteinsNevus, PigmentedSkin NeoplasmsTissue Array Analysis